Naturally Splendid Launches New Corporate Website and Provides Strategic Update

(TheNewswire)





Naturally Splendid Enterprises Ltd. ("Naturally Splendid") (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce the new Corporate website is now live at www.naturallysplendid.com

In addition to the new Corporate website, the Company will be systematically updating the individual Company brand websites to enhance consumer experience and improve the e-commerce procedure and experience.

Company Vice President of Operations Mr. Bryan Carson states, " We felt it timely to put into perspective the plant based history of Naturally Splendid and we invite you to take a minute to review our website to understand where the Company is today and equally as important, where the Company is heading for the remainder of 2020, into 2021 and beyond ".

From the beginning, Naturally Splendid has focused on plant-based foods and the unlimited potential of plant nutrition for the betterment of people and the planet. The first product launch was based on the superfood hemp, an agriculturally friendly crop that is rich in protein, omegas, fibre and other macro nutrients. This in fact, was the impetus that set the wheels in motion to deliver plant derived nutrition.

Naturally Splendid's 100% owned Prosnack Natural Foods division operates a Safe Quality Food (SQF) certified manufacturing facility producing our own plant-based products as well as provides contract manufacturing services for a variety of clients.

Through the Plasm Pharmaceutical joint venture with Biologic Pharmamedical, the Company continues to pursue a phase 2 clinical trial for a potential COVID-19 treatment utilizing the target drug Cavaltinib TM , a curcumin extract derived from a Biologic patented technology.

The Company has made a presence in plant-based markets through Company owned brands such as NATERA Sport. The recent announcement of NATERA Plant Based Foods, further positions the Company in one of the fastest growing consumer driven markets in North America, plant-based nutrition.

After extensive review, testing and strategizing, NATERA Plant Based Foods have selected 20 plant-based products in total that will be introduced to North America for the first time ever.

The NATERA Plant Based Foods initial product launch includes meatless; schnitzel, Kiev, nuggets, sweet chili strips, garlic bites as well as burgers. These six (6) products are available immediately through food service and we will be introducing the twenty products through various retail and food service channels in a systematic on-going strategy.


NATERA Plant Based Foods already has a range of products far wider than most every meat alternative company in North America. However, R&D with our strategic partners developing new products for this rapidly growing consumer space will continue, to further extend product lines.

Naturally Splendid CEO, Mr. J. Craig Goodwin states, " We have remained true to our roots from the beginning and that is to focus on quality plant-based products. Whether it is our SQF manufacturing facility Prosnack, the phase 2 clinical trial for a potential COVID-19 treatment, or our NATERA product lines, our products and operations common thread is plants. Our mission is to be inclusive with our plant-based nutrition whether you are vegetarian, flexitarian or if you simply like great tasting food and are looking for plant-based nutrition for your own personal reasons. We look forward to delivering on this commitment and delivering nutritious, delicious products for this rapidly growing market ."

About Naturally Splendid Enterprises Ltd.

NSE operates a Safe Quality Food Level 2 certified food manufacturing facility just outside Vancouver, BC in Canada. We have established numerous healthy, functional foods under recognized brands such as Natera Sport (TM), Natera Hemp Foods (TM), CHII (TM), Elevate Me (TM) and Woods Wild Bar (TM). The Company has a myriad of new products and line extensions under development that are approaching launch. NSE has also developed proprietary technologies for the extraction of high demand, healthy omega 3 and 6 oils from hemp. NSE is the current "go-to" manufacturer for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many global healthy food companies, private labelling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573

On Behalf of the Board of Directors

Mr. J. Craig Goodwin

CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.

(NSP - TSX Venture; NSPDF - OTCQB; 50N Frankfurt)

#108-19100 Airport Way

Pitt Meadows, BC, V3Y 0E2

Office: (604) 465-0548

Fax: (604) 465-1128

E-mail: info@naturallysplendid.com

Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Copyright (c) 2020 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
Radiopharm Theranostics

Quarterly Activities & Cash Report and 4C for the Quarter ended 30 September 2024

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world‐class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to provide a summary of its activities for the quarter ended 30 September 2024.

Keep reading...Show less

AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The dividend will be paid on December 9, 2024 to all stockholders of record as of the close of business on November 18, 2024 .

About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Scientist using microscope.

Biotech Market Update: Q3 2024 in Review

The biotech sector in Q3 2024 experienced a dynamic landscape characterized by advancements in AI-powered drug discovery and fluctuating venture capital investments.

Investors exercised caution and restraint due to the economic outlook; however, the potential of artificial intelligence (AI) to revolutionize healthcare remained a focal point.

Here, the Investing News Network delves into the key trends and developments that shaped the biotech sector during Q3, highlighting the interplay of innovation, investment, and regulatory considerations.

Keep reading...Show less

AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Agreements to Establish Indonesian-Based Seaweed Business and Capital Raising

Further to previous announcements made by the Board of BPH Global Ltd (ASX: BP8) (Company) regarding the Company’s strategic review of its seaweed operations and the expansion of its R&D operations to include the extraction of minerals and gases for use in the battery and energy industries, the Board is pleased to announce that the Company has entered into a binding term sheet to acquire Indonesian-based seaweed assets and for the joint development of an Indonesian- based seaweed business.

Keep reading...Show less
Cardiol Therapeutics to Advance CardiolRx into a Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics to Advance CardiolRx into a Late-Stage Trial in Patients with Recurrent Pericarditis

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced plans to expand the MAVERIC clinical development program and advance CardiolRx™ into a late-stage clinical trial ("MAVERIC-2") to evaluate the impact of CardiolRx™ in recurrent pericarditis patients following cessation of interleukin-1 ("IL-1") blocker therapy. MAVERIC-2 is expected to be initiated during Q4 at major pericardial disease centres in the United States and Europe and to report results ahead of the Company's planned pivotal Phase III study in recurrent pericarditis.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×